Harvard Management Company’s AbCellera Biologics ABCL Stock Holding History

Harvard Management Company’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-4,105,095	Closed	-$31M	–	34
2023 Q1	$31M	Hold	4,105,095	–	–	3.25%	5
2022 Q4	$41.6M	Hold	4,105,095	–	–	5.16%	5
2022 Q3	$40.6M	Hold	4,105,095	–	–	5.05%	4
2022 Q2	$43.7M	Hold	4,105,095	–	–	5.06%	4
2022 Q1	$40M	Hold	4,105,095	–	–	4.04%	4
2021 Q4	$58.7M	Hold	4,105,095	–	–	5.51%	5
2021 Q3	$82.3M	Hold	4,105,095	–	–	4.82%	7
2021 Q2	$90.3M	Hold	4,105,095	–	–	5.2%	6
2021 Q1	$139M	Hold	4,105,095	–	–	7.79%	4
2020 Q4	$165M	Buy	+4,105,095	New	+$188M	8.96%	4

Other funds holding ABCL

Baillie Gifford & Co

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VOYA Investment Management

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Capital World Investors

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Federated Hermes

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return